Literature DB >> 25015941

EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.

Hidemasa Matsuo1, Mio Kajihara1, Daisuke Tomizawa2, Tomoyuki Watanabe3, Akiko Moriya Saito4, Junichiro Fujimoto5, Keizo Horibe4, Kumi Kodama1, Mayu Tokumasu6, Hiroshi Itoh1, Hideki Nakayama7, Akitoshi Kinoshita8, Takashi Taga9, Akio Tawa10, Tomohiko Taki11, Norio Shiba12, Kentaro Ohki13, Yasuhide Hayashi13, Yuka Yamashita14, Akira Shimada15, Shiro Tanaka16, Souichi Adachi17.   

Abstract

Entities:  

Keywords:  EVI1; MLL; acute myeloid leukemia; pediatrics; prognostic factor

Mesh：

Substances：

Year:  2014        PMID： 25015941      PMCID： PMC4222468          DOI： 10.3324/haematol.2014.107128

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

2.  Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.

Authors:  Shunya Arai; Akihide Yoshimi; Munetake Shimabe; Motoshi Ichikawa; Masahiro Nakagawa; Yoichi Imai; Susumu Goyama; Mineo Kurokawa
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

3.  High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.

Authors:  Phoenix A Ho; Todd A Alonzo; Robert B Gerbing; Jessica A Pollard; Betsy Hirsch; Susana C Raimondi; Todd Cooper; Alan S Gamis; Soheil Meshinchi
Journal:  Br J Haematol       Date:  2013-07-04       Impact factor: 6.998

4.  EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Authors:  Eric M J Bindels; Marije Havermans; Sanne Lugthart; Claudia Erpelinck; Elizabeth Wocjtowicz; Andrei V Krivtsov; Elwin Rombouts; Scott A Armstrong; Erdogan Taskesen; Jurgen R Haanstra; H Berna Beverloo; Hartmut Döhner; Wendy A Hudson; John H Kersey; Ruud Delwel; Ashish R Kumar
Journal:  Blood       Date:  2012-05-02       Impact factor: 22.113

5.  Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines.

Authors:  K Morishita; D S Parker; M L Mucenski; N A Jenkins; N G Copeland; J N Ihle
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

6.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Authors:  Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

7.  Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

Authors:  Stefan Gröschel; Richard F Schlenk; Jan Engelmann; Veronika Rockova; Veronica Teleanu; Michael W M Kühn; Karina Eiwen; Claudia Erpelinck; Marije Havermans; Michael Lübbert; Ulrich Germing; Ingo G H Schmidt-Wolf; H Berna Beverloo; Gerrit J Schuurhuis; Gert J Ossenkoppele; Brigitte Schlegelberger; Leo F Verdonck; Edo Vellenga; Gregor Verhoef; Peter Vandenberghe; Thomas Pabst; Mario Bargetzi; Jürgen Krauter; Arnold Ganser; Peter J M Valk; Bob Löwenberg; Konstanze Döhner; Hartmut Döhner; Ruud Delwel
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

8.  High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Authors:  Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Wim L J van Putten; Peter J M Valk; Sonja van der Poel-van de Luytgaarde; Ronald Hack; Rosalyn Slater; Elisabeth M E Smit; H Berna Beverloo; Gregor Verhoef; Leo F Verdonck; Gert J Ossenkoppele; Pieter Sonneveld; Georgine E de Greef; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

9.  Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity.

Authors:  Keisuke Kataoka; Tomohiko Sato; Akihide Yoshimi; Susumu Goyama; Takako Tsuruta; Hiroshi Kobayashi; Munetake Shimabe; Shunya Arai; Masahiro Nakagawa; Yoichi Imai; Keiki Kumano; Katsuyoshi Kumagai; Naoto Kubota; Takashi Kadowaki; Mineo Kurokawa
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

10.  Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Authors:  Daisuke Tomizawa; Akio Tawa; Tomoyuki Watanabe; Akiko Moriya Saito; Kazuko Kudo; Takashi Taga; Shotaro Iwamoto; Akira Shimada; Kiminori Terui; Hiroshi Moritake; Akitoshi Kinoshita; Hiroyuki Takahashi; Hideki Nakayama; Nobutaka Kiyokawa; Keiichi Isoyama; Shuki Mizutani; Junichi Hara; Keizo Horibe; Tatsutoshi Nakahata; Souichi Adachi
Journal:  Int J Hematol       Date:  2013-09-26       Impact factor: 2.490
View more
  12 in total

1.  Purification of leukemic blast cells from blood smears using laser microdissection.

Authors:  Hidemasa Matsuo; Shuichi Shiga; Tsuyoshi Imai; Yasuhiko Kamikubo; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Souichi Adachi
Journal:  Int J Hematol       Date:  2017-04-13       Impact factor: 2.490

2.  The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.

Authors:  Marion Eveillard; Jacques Delaunay; Steven Richebourg; Laurence Lodé; Richard Garand; Soraya Wuillème; François Duhoux; Hélène Antoine-Poirel; Catherine Godon; Marie C Béné
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

3.  The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Susumu Goyama; Yasuhiko Kamikubo; Souichi Adachi
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

4.  Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.

Authors:  X He; Q Wang; J Cen; H Qiu; A Sun; S Chen; D Wu
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

5.  The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.

Authors:  Shuhui Jiang; Yi Fan; Yanglan Fang; Chang Hou; Jia Chen; Jiannong Cen; Huiying Qiu; Suning Chen; Yang Xu; Depei Wu
Journal:  Bone Marrow Transplant       Date:  2020-09-05       Impact factor: 5.483

6.  Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

Authors:  Norio Shiba; Kenichi Yoshida; Yusuke Hara; Genki Yamato; Yuichi Shiraishi; Hidemasa Matsuo; Yusuke Okuno; Kenichi Chiba; Hiroko Tanaka; Taeko Kaburagi; Masanobu Takeuchi; Kentaro Ohki; Masashi Sanada; Jun Okubo; Daisuke Tomizawa; Tomohiko Taki; Akira Shimada; Manabu Sotomatsu; Keizo Horibe; Takashi Taga; Souichi Adachi; Akio Tawa; Satoru Miyano; Seishi Ogawa; Yasuhide Hayashi
Journal:  Blood Adv       Date:  2019-10-22

Review 7.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.

Authors:  Hidemasa Matsuo; Kenichi Yoshida; Kana Nakatani; Yutarou Harata; Moe Higashitani; Yuri Ito; Yasuhiko Kamikubo; Yusuke Shiozawa; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Ai Okada; Yasuhito Nannya; June Takeda; Hiroo Ueno; Nobutaka Kiyokawa; Daisuke Tomizawa; Takashi Taga; Akio Tawa; Satoru Miyano; Manja Meggendorfer; Claudia Haferlach; Seishi Ogawa; Souichi Adachi
Journal:  Blood Adv       Date:  2020-10-13

9.  Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.

Authors:  Yong-Mei Zhu; Pan-Pan Wang; Jin-Yan Huang; Yun-Shuo Chen; Bing Chen; Yu-Jun Dai; Han Yan; Yi Hu; Wen-Yan Cheng; Ting-Ting Ma; Sai-Juan Chen; Yang Shen
Journal:  J Transl Med       Date:  2017-08-22       Impact factor: 5.531

10.  EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.

Authors:  Yusuke Saito; Daisuke Sawa; Mariko Kinoshita; Ai Yamada; Sachiyo Kamimura; Akira Suekane; Honami Ogoh; Hidemasa Matsuo; Souichi Adachi; Takashi Taga; Daisuke Tomizawa; Motomi Osato; Tomoyoshi Soga; Kazuhiro Morishita; Hiroshi Moritake
Journal:  Haematologica       Date:  2019-10-24       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.